Scotiabank raised the firm’s price target on Disc Medicine (IRON) to $70 from $62 and keeps an Outperform rating on the shares. The firm views the company’s end-of-phase 2 FDA meeting update as a “home run” given alignment on all proposed endpoints for its phase 3 trial design to assess bitopertin, the analyst tells investors. The trial will assess bitopertin in erythropoietic protoporphyria and X-linked protoporphyria and, while the two are rare, the firm believes bitopertin will capture meaningful market share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRON:
- Disc Medicine upgraded to Overweight from Equal Weight at Morgan Stanley
- Disc Medicine price target raised to $112 from $70 at BMO Capital
- Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’
- Disc Medicine upgraded to Strong Buy from Outperform at Raymond James
- Disc Medicine Gains FDA Support for Bitopertin Trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
